SCIENCE
MYC drives tumor aggressiveness, therapeutic resistance, and the formation of an immunosuppressive tumor microenvironment (TME). Aberrant MYC expression or activity is implicated in up to 70% of human cancers. Despite its central role in oncogenesis, MYC has long been considered biologically “undruggable” as a direct therapeutic target.
Rather than attempting to inhibit MYC directly, our strategy is to identify and target MYC-associated vulnerabilities to eliminate cancer through synthetic lethality. We have identified MKLP2 as a critical dependency in MYC-driven tumors and developed the SYMPLEX™ platform to discover selective MKLP2 inhibitors.
A self-renewing discovery engine that generates, screens, and optimizes MYC synthetic lethality drug candidates with novel mechanisms.
GUNS-DF (General utility new scaffold-drug fragment)
MIPS (Mechanism-Informed Phenotypic Screening)
DrugGPT (An AI Drug Discovery & Integration Sysytem)
